Treatments for primary mediastinal B-cell lymphoma
The following are treatment options for primary mediastinal B-cell lymphoma. The healthcare team will suggest treatments based on your child’s needs and work with you to develop a treatment plan. Treatments are often based on the stage or risk group.
Chemotherapy is the main treatment for primary mediastinal B-cell lymphoma. Chemotherapy often includes targeted therapy drugs.
Chemotherapy drugs are given in different combinations based on different treatment plans (called protocols). The most common chemotherapy combination used is:
- etoposide (Vepesid, VP-16)
- doxorubicin (Adriamycin)
- cyclophosphamide (Cytoxan, Procytox)
- vincristine (Oncovin)
- rituximab (Rituxan)
Intrathecal chemotherapy may be given to prevent spread of NHL to the brain and spinal cord (called the central nervous system, or CNS) or to treat NHL that has spread to the CNS. This means that the drugs are given directly into the cerebrospinal fluid (CSF) around the brain and spinal cord. Intrathecal chemotherapy can include 1 to 3 of the following drugs:
Targeted therapy with rituximab may be used to treat children with primary mediastinal B-cell lymphoma, in combination with chemotherapy, in a clinical trial setting.
Many children with childhood primary mediastinal B-cell lymphoma will be treated in a clinical trial that is tailored to the risk group or stage of their disease. The clinical trial protocol, or plan, outlines the treatments used (such as chemotherapy or targeted therapy), as well as the drugs and dosages used. Find out more about clinical trials.